Compare AbbVie Inc (ABBV) vs Ecopetrol SA (EC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Ecopetrol SA — how do they compare? AbbVie Inc trades at $253.78 (market cap $449.91B), while Ecopetrol SA trades at $15.03 (market cap $28.19B). The key difference: AbbVie Inc is far larger — about 16× Ecopetrol SA's market cap, and Ecopetrol SA pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| ABBV | EC | |
|---|---|---|
Market Cap | $449.91B | $28.19B |
Sector | Health | Energy |
52-Week High | $261.07 | $16.58 |
52-Week Low | $184.85 | $8.29 |
Enterprise Value | $513.38B | $55.97B |
Dividend Yield | 2.72% | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Ecopetrol (EC) trades at $14.69, slightly below the consensus price target of $14.63, with a bearish technical signal and mixed earnings performance. Recent quarters show misses against EPS expectations, while revenue has declined from $159.6T in 2022 to $119.7T in 2025. The company maintains a dividend payout, with a recent H1-26 dividend of $0.66, and holds a BB- credit rating with a stable outlook as affirmed by S&P Global Ratings on June 17, 2026.
The outlook remains cautious due to declining revenue and profitability trends, offset by attractive valuation multiples like a P/E of 10.31. Key risks include operational execution in the energy sector and macroeconomic pressures on oil demand. Analyst sentiment is mixed with a Hold-dominated consensus, suggesting limited near-term upside potential amid ongoing fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
